Human Genome Sciences (HGS) has reported continuation data from a Phase II study of BENLYSTA™ (belimumab, formerly LymphoStat-B®) showing sustained improvement in patients with active systemic lupus after four years of treatment. The data was presented at the EULAR 2009 scientific meeting in Copenhagen, Denmark.
Early results from a 52-week Phase III study of BENLYSTA™ are expected to be announced in July and results from a 76-week study are scheduled to be released in November.
BENLYSTA™ is being co-developed and commercialized by HGS and GlaxoSmithKline (GSK).
The HGS website has the full release about this additional Phase II data.
Source
Lupus Foundation of America
View drug information on Benlysta.